400 related articles for article (PubMed ID: 20532833)
1. A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis.
Younossi ZM; Page S; Rafiq N; Birerdinc A; Stepanova M; Hossain N; Afendy A; Younoszai Z; Goodman Z; Baranova A
Obes Surg; 2011 Apr; 21(4):431-9. PubMed ID: 20532833
[TBL] [Abstract][Full Text] [Related]
2. Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease.
Tanwar S; Trembling PM; Guha IN; Parkes J; Kaye P; Burt AD; Ryder SD; Aithal GP; Day CP; Rosenberg WM
Hepatology; 2013 Jan; 57(1):103-11. PubMed ID: 22930399
[TBL] [Abstract][Full Text] [Related]
3. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease.
Malik R; Chang M; Bhaskar K; Nasser I; Curry M; Schuppan D; Byrnes V; Afdhal N
J Gastroenterol Hepatol; 2009 Apr; 24(4):564-8. PubMed ID: 19378390
[TBL] [Abstract][Full Text] [Related]
4. Nonalcoholic fatty liver disease: biomarkers as diagnostic tools for liver damage assessment in adult patients from Argentina.
Valva P; Rios D; Casciato P; Gadano A; Galdame O; Mullen E; Bertot G; de Matteo E; Preciado MV
Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):637-644. PubMed ID: 29384795
[TBL] [Abstract][Full Text] [Related]
5. Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness.
Liebig S; Stoeckmann N; Geier A; Rau M; Schattenberg JM; Bahr MJ; Manns MP; Jaeckel E; Schulze-Osthoff K; Bantel H
Clin Transl Gastroenterol; 2019 Aug; 10(8):e00066. PubMed ID: 31397685
[TBL] [Abstract][Full Text] [Related]
6. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH).
Younossi ZM; Jarrar M; Nugent C; Randhawa M; Afendy M; Stepanova M; Rafiq N; Goodman Z; Chandhoke V; Baranova A
Obes Surg; 2008 Nov; 18(11):1430-7. PubMed ID: 18500507
[TBL] [Abstract][Full Text] [Related]
7. Plasma N-terminal propeptide of type III procollagen accurately predicts liver fibrosis severity in children with non-alcoholic fatty liver disease.
Mosca A; Comparcola D; Romito I; Mantovani A; Nobili V; Byrne CD; Alisi A; Targher G
Liver Int; 2019 Dec; 39(12):2317-2329. PubMed ID: 31436362
[TBL] [Abstract][Full Text] [Related]
8. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
[TBL] [Abstract][Full Text] [Related]
9. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis.
Vali Y; Lee J; Boursier J; Spijker R; Löffler J; Verheij J; Brosnan MJ; Böcskei Z; Anstee QM; Bossuyt PM; Zafarmand MH;
J Hepatol; 2020 Aug; 73(2):252-262. PubMed ID: 32275982
[TBL] [Abstract][Full Text] [Related]
10. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease.
Cusi K; Chang Z; Harrison S; Lomonaco R; Bril F; Orsak B; Ortiz-Lopez C; Hecht J; Feldstein AE; Webb A; Louden C; Goros M; Tio F
J Hepatol; 2014 Jan; 60(1):167-74. PubMed ID: 23973932
[TBL] [Abstract][Full Text] [Related]
11. Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver disease.
Ergelen R; Akyuz U; Aydin Y; Eren F; Yilmaz Y
Eur J Gastroenterol Hepatol; 2015 Jun; 27(6):667-71. PubMed ID: 25923941
[TBL] [Abstract][Full Text] [Related]
12. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis.
Yilmaz Y; Dolar E; Ulukaya E; Akgoz S; Keskin M; Kiyici M; Aker S; Yilmaztepe A; Gurel S; Gulten M; Nak SG
World J Gastroenterol; 2007 Feb; 13(6):837-44. PubMed ID: 17352011
[TBL] [Abstract][Full Text] [Related]
13. Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis.
Loomba R; Jain A; Diehl AM; Guy CD; Portenier D; Sudan R; Singh S; Faulkner C; Richards L; Hester KD; Okada L; Li XJ; Mimms L; Abdelmalek MF
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1867-1876.e3. PubMed ID: 30448594
[TBL] [Abstract][Full Text] [Related]
14. Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers.
Shen J; Chan HL; Wong GL; Chan AW; Choi PC; Chan HY; Chim AM; Yeung DK; Yu J; Chu WC; Wong VW
Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1057-66. PubMed ID: 23066946
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis.
Lee J; Vali Y; Boursier J; Duffin K; Verheij J; Brosnan MJ; Zwinderman K; Anstee QM; Bossuyt PM; Zafarmand MH
PLoS One; 2020; 15(9):e0238717. PubMed ID: 32915852
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
Verma S; Jensen D; Hart J; Mohanty SR
Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
[TBL] [Abstract][Full Text] [Related]
17. Limited utility of plasma M30 in discriminating non-alcoholic steatohepatitis from steatosis--a comparison with routine biochemical markers.
Chan WK; Sthaneshwar P; Nik Mustapha NR; Mahadeva S
PLoS One; 2014; 9(9):e105903. PubMed ID: 25184298
[TBL] [Abstract][Full Text] [Related]
18. Will non-invasive markers replace liver biopsy for diagnosing and staging fibrosis in non-alcoholic steatohepatitis?
Hashimoto E; Farrell GC
J Gastroenterol Hepatol; 2009 Apr; 24(4):501-3. PubMed ID: 19368628
[No Abstract] [Full Text] [Related]
19. Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis.
Kozumi K; Kodama T; Murai H; Sakane S; Govaere O; Cockell S; Motooka D; Kakita N; Yamada Y; Kondo Y; Tahata Y; Yamada R; Hikita H; Sakamori R; Kamada Y; Daly AK; Anstee QM; Tatsumi T; Morii E; Takehara T
Hepatology; 2021 Nov; 74(5):2452-2466. PubMed ID: 34105780
[TBL] [Abstract][Full Text] [Related]
20. Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations.
Younossi ZM; Noureddin M; Bernstein D; Kwo P; Russo M; Shiffman ML; Younes Z; Abdelmalek M
Am J Gastroenterol; 2021 Feb; 116(2):254-262. PubMed ID: 33284184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
